---
title: "Agios Pharmaceuticals, Inc. (AGIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AGIO.US.md"
symbol: "AGIO.US"
name: "Agios Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-03-13T13:45:08.660Z"
locales:
  - [en](https://longbridge.com/en/quote/AGIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AGIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AGIO.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AGIO.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AGIO.US.md)


# Agios Pharmaceuticals, Inc. (AGIO.US)

## Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.agios.com](https://www.agios.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:16.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 102 / 404 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 48.03% |  |
| Net Profit YoY | -161.27% |  |
| P/B Ratio | 1.35 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1616558025.48 |  |
| Revenue | 54028000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -30.20% | E |
| Profit Margin | -764.01% | E |
| Gross Margin | -540.19% | E |
| Revenue YoY | 48.03% | A |
| Net Profit YoY | -161.27% | E |
| Total Assets YoY | -22.00% | E |
| Net Assets YoY | -22.57% | E |
| Cash Flow Margin | -13.09% | D |
| OCF YoY | 48.03% | A |
| Turnover | 0.04 | E |
| Gearing Ratio | 8.03% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Agios Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "48.03%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-161.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1616558025.48",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "54028000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-30.20%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-764.01%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-540.19%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "48.03%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-161.27%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.00%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.57%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-13.09%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "48.03%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.03%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.92 | 351/404 | 3.47 | 3.14 | 2.58 |
| PB | 1.35 | 114/404 | 1.60 | 1.34 | 1.18 |
| PS (TTM) | 29.92 | 216/404 | 55.79 | 48.78 | 35.75 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-12T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Hold | 3 | 30% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.90 |
| Highest Target | 65.00 |
| Lowest Target | 28.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AGIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AGIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AGIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AGIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**